After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
We are very excited to launch our new website! Please take a few moments to click around and explore...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...